Physician profile
Lan T Mahon
NPI 1346240355
$804.75
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $805.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $155.15 | 2019 | |
| Amarin Pharma, INC. | $131.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.41 | 2019 | |
| Amgen INC. | $76.17 | 2019 | |
| Astellas Pharma US INC | $75.61 | 2019 | |
| Merck Sharp & Dohme LLC | $59.98 | 2019 | |
| Shire North American Group INC | $35.83 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $31.36 | 2019 | |
| Glaxosmithkline, LLC. | $31.33 | 2019 | |
| Abbvie INC. | $23.83 | 2019 | |
| Genentech USA, INC. | $15.45 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.44 | 2019 | |
| Horizon Therapeutics Plc | $14.95 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.32 | 2019 | |
| Adlon Therapeutics L.P. | $13.44 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lan Mahon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.